Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings is supported by a durable KIMMTRAK franchise, with management reporting no deterioration in underlying demand, normalized distributor inventory, and about 14 months of treatment duration, while the estimated $6.5 million stocking reversal and roughly $5 million prior-year extra selling week appear to be timing items rather than demand weakness. Its long-term upside is strengthened by a diversified ImmTAX pipeline, including PRAME and autoimmune assets, with brenetafusp retaining a multi-year lead in randomized registrational development and early KIMMTRAK-brenetafusp data showing a 29% ORR, 24.1-month median response duration, 8.1-month median PFS, and 70% two-year OS in 17 evaluable patients. Management’s progress across melanoma, ovarian cancer, and other programs, combined with an estimated $15/share platform value and a more stable underlying revenue growth profile after normalization, supports a constructive fundamental outlook.

Immunocore Holdings is facing a weaker fundamental setup as its key uveal melanoma catalyst slipped to an expected 2Q27 OS readout from prior end-2026 timing, pushing commercialization later and reducing near-term conviction amid an increasingly competitive melanoma backdrop. 3Q26 revenue of $102.2 million missed estimates, KIMMTRAK sales fell 1.4% year over year, and the company still expects a roughly $120 million rebate-related payment in 4Q26, which pressures near-term cash generation despite $901.3 million in cash and marketable securities. While the pipeline remains broad, the cited commercialization timelines for KIMMTRAK and brenetafusp were pushed out to 2028E/2029E and 2030E/2031E, respectively, reinforcing dilution, execution, and clinical-development risk.